Abraxane
Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong
April 4, 2019Business Services, Sales and Marketing Abraxane, Celgene, Cynviloq, Patrick Soon-Shiong, Sorrento, lawsuits
Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA …
Celgene’s Abraxane combo flops in phase 3 cancer trials
March 14, 2019Research and Development Abraxane, Celgene, clinical trials, pharma, trials
Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …
Wales approve pancreatic cancer drug for use despite NICE rejection in England
March 18, 2016Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval
Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
Allergan files ANDA for generic version of Celgene’s breast cancer treatment
March 18, 2016Business Services, Medical Communications, Sales and Marketing Abraxane, Allergan, Celgene, breast cancer, generic
Allergan (NYSE: AGN) said it is seeking regulatory approval for a generic version of biotech firm Celgene’s (Nasdaq: CELG) breast …
Two Celgene cancer drugs approved in Ireland
March 1, 2016Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid
Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …
NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’
September 17, 2015Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer
NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …
Celgene UK: market access is a complex business
December 15, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce
Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …
Celgene rebuffed by NICE over cancer drug
September 9, 2014Sales and Marketing Abraxane, Cancer, Celgene, Gemzar, NICE, gemcitabine, nab-paclitaxel
In new draft guidance NICE says that Celgene’s Abraxane (nab-paclitaxel) taken with Lilly’s Gemzar (gemcitabine) should not be funded by …
Cancer treatment Abraxane gets EU nod
January 9, 2014Sales and Marketing Abraxane, Cancer, Celgene, EU, pancreatic
Celgene’s cancer drug Abraxane has been approved by European regulators to treat patients with metastatic adenocarcinoma of the pancreas, or …
Celgene completes Abraxis takeover
October 15, 2010Research and Development, Sales and Marketing Abraxane, Abraxis, Celgene, mergers and acquisitions, oncology
Celgene has completed its acquisition of Abraxis BioScience for cash and stock totalling $2.9 billion. The takeover gives the cancer …
Celgene
January 1, 2010Research and Development, Sales and Marketing Abraxane, Celgene, Revlimid, Thalidomide
Founded in 1986, Celgene was created as a spin off from the Celanese Corporation. Two years later, the company received …
